Back to top
more

Mersana Therapeutics (MRSN)

(Delayed Data from NSDQ)

$3.52 USD

3.52
2,603,424

-0.24 (-6.38%)

Updated Apr 17, 2024 04:00 PM ET

After-Market: $3.52 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?

by Zacks Equity Research

Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of 20% and 62.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -20.51% and 54.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -2,300% and 85.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 26.92% and 15.53%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More

by Zacks Equity Research

Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.

Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold

by Zacks Equity Research

Mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to treat platinum-sensitive ovarian cancer.

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -26.83% and 62.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 17.19% and 22.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More

by Zacks Equity Research

Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.

Zai Lab Limited Unsponsored ADR (ZLAB) Soars 17.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1,933.33% and 85.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -11.96% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?

by Zacks Equity Research

Here is how Aerie Pharmaceuticals (AERI) and Mersana Therapeutics, Inc. (MRSN) have performed compared to their sector so far this year.

Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals

by Zacks Equity Research

Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates

by Zacks Equity Research

Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Mersana Therapeutics, Inc. (MRSN)? Wall Street Analysts Think 256%

by Zacks Equity Research

The mean of analysts' price targets for Mersana Therapeutics, Inc. (MRSN) points to a 255.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?

by Zacks Equity Research

Beam Therapeutics Inc. (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.